Form 8-K - Current report:
SEC Accession No. 0001367644-22-000099
Filing Date
2022-06-07
Accepted
2022-06-07 06:43:15
Documents
13
Period of Report
2022-06-06
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20220606.htm   iXBRL 8-K 36345
  Complete submission text file 0001367644-22-000099.txt   189848

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20220606.xsd EX-101.SCH 2218
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20220606_def.xml EX-101.DEF 2933
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20220606_lab.xml EX-101.LAB 27198
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20220606_pre.xml EX-101.PRE 14705
7 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20220606_htm.xml XML 11009
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 22999788
SIC: 2834 Pharmaceutical Preparations